Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 4, 2010, Pages 613-619

  Andrade Chebli, Liliana ^a   De Miranda Chaves, Leonardo Duque ^a   Ferreira Pimentel, Felipe ^a   Martins Guerra, Dolores ^a   De Freitas Barros, Renata Maria ^a   Duarte Gaburri, Pedro ^a   Zanini, Alexandre ^a   Fonseca Chebli, Julio Maria ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

Azathioprine; Corticosteroids; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISONE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADD ON THERAPY; ADULT; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FEVER; HEPATITIS; HUMAN; HUMAN TISSUE; LEUKOPENIA; MALE; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; RISK; RISK BENEFIT ANALYSIS; SAFETY; ULCERATIVE COLITIS; VOMITING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AZATHIOPRINE; COHORT STUDIES; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949522476     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21083     Document Type: Article

References (33)

1. Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447.
2. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A): 5-36.
3. Hanauer SB. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. Aliment Pharmacol Ther. 2008; 27(suppl 1):15-21.
4. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008;14:354-377.
5. Faubion WA, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a populationbased study. Gastroenterology. 2001;121:255-260.
6. Carter MJ, Lobo AJ, Travis SPL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(suppl V):S1-16.
7. Irving PM, Gearry RB, Sparrow MP, et al. Appropriate use of corticosteroids in Crohn's disease. Aliment Pharmacol Ther. 2007;26: 313-329.
8. Ginsburg PM, Dassopoulos T. Steroid dependent ulcerative colitis: azathioprine use is finally "evidence-based." Inflamm Bowel Dis. 2006; 12:921-922.
9. Kornbluth A, Sachar D. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
10. Ghosh S, Chaudhary R, Carpani M, et al. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut. 2006;55:6-8.
11. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut. 2006;55:437-441.
12. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
13. Leung Y, Panaccione R, Hemmelgarn B, et al. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2008;53:1455-1461.
14. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
15. Stange EF, Travis SP, Vermeire S, et al. European evidence based consensus on the diagnosis and management of ulcerative colitis: defi-nitions and diagnosis. J Crohn's Colitis. 2008;2:1-23.
16. D'Haens G, Sandborn WJ, Feagan BG, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132:763-786.
17. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
18. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974;4:627-630.
19. Rosemberg JL, Wall AJ, Levine B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69:96-99.
20. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J. 1982;284:1291-1292.
21. Hawthorne AB, Logan RFA, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J. 1992;305:20-22.
22. Matè-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
23. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one year, placebo controlled, randomised trial. Indian J Gastroenterol. 2000;19:14-16.
24. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisolone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
25. Chebli JM, Gaburri PD, De Souza AF, et al. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol. 2007; 22:268-274.
26. Warman JI, Korelitz BI, Fleisher MR, et al. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol. 2003;37:220-225.
27. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
28. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
29. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep. 2008;10: 568-575.
30. Higgins PDR, Schwartz M, Mapili J, et al. Patient-defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
31. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11-24.
32. Panaccione R, Rutgeersts P, Sandborn WJ, et al. Treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688.
33. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796-800.